Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
APMD
HoldApnimed, Inc. · Healthcare · United States · $1.2B
36
StockRankGet insider-trade alerts
Q
54
V
50
M
22
P/E (TTM)
8.6x
ROE
—
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Apnimed, Inc. is a clinical-stage pharmaceutical company focused on the development of oral medications for the treatment of obstructive sleep apnea. Its competitive position relies on its proprietary pharmacological approach, aiming to offer the first pill-based alternative to current mechanical devices like CPAP machines.
Loading 1Y...
PRICE (1Y)+18.8%
Close
$29.71
RSI (14)
53.7
SCORE BREAKDOWN
Quality
54
ROIC (ROA)
-1.3%*44.9
ROE
—N/A
GP/Assets
154.5%99.3
Op. Margin
80.2%99.2
FCF/Assets
—N/A
Piotroski
239.7
Int. Cover
—89.3
D/E Ratio
—N/A
Current Ratio
1.91x36.9
Value
50
P/E (TTM)
8.6x91.9
EV/EBITDA
9.5x71.0
P/FCF
—N/A
P/B
-0.5x25.0
P/S
9.8x27.4
Div Yield
—N/A
Momentum
22
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-140%3.8
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.2B
P/E (Forward)
-21.3x
Gross Margin
93.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of APMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| APMD | Apnimed, Inc.(you) | $1.2B | 36 | Hold |
| SLDB | Solid Biosciences Inc. | $1.0B | 38 | Hold |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 34 | Sell |
| IMMX | Immix Biopharma, Inc. | $992M | 34 | Sell |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 33 | Sell |
| LBRX | LB Pharmaceuticals Inc | $1.5B | 34 | Sell |
| BCAX | Bicara Therapeutics Inc. | $1.6B | 34 | Sell |
| CADL | Candel Therapeutics, Inc. | $1.0B | 31 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 29 | Sell |
Peer medians: ROE -24.7% · P/E 31.1x · Gross margin 58.8%